MALVERN, Pa., Oct. 25 /PRNewswire-FirstCall/ -- Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL - News) today announced positive data from two Phase II trials that were presented at the American Urology Association's (AUA) western sectional meeting in Maui, Hawaii. These data showed that AA4500, an injectable enzyme, appeared to be effective and generally well tolerated in treating patients with Peyronie's Disease. In these studies, treatment with AA4500 resulted in 89 percent of patients who received a three-treatment series of three injections each achieving clinical success, which was defined as change from baseline in deviation angle of at least 25 percent. This improvement was maintained through the end of the study follow up period at nine months. BioSpecifics Technologies Corp., licensor of AA4500, sponsored and monitored the trials.
